Last reviewed · How we verify
Placebo for Risankizumab SC — Competitive Intelligence Brief
phase 3
Immunology
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo for Risankizumab SC (Placebo for Risankizumab SC) — AbbVie. This is a placebo control used in clinical trials to compare against risankizumab, an IL-23 inhibitor.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo for Risankizumab SC TARGET | Placebo for Risankizumab SC | AbbVie | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo for Risankizumab SC CI watch — RSS
- Placebo for Risankizumab SC CI watch — Atom
- Placebo for Risankizumab SC CI watch — JSON
- Placebo for Risankizumab SC alone — RSS
Cite this brief
Drug Landscape (2026). Placebo for Risankizumab SC — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-for-risankizumab-sc. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing